Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

11 treatments under study, led by Adtsecondgeneration Antiandrogens Chemotherapy

Research Leaders

13 sponsors active, led by Affiliated Hospital of Nantong University

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 6 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

6Total
Not Applicable (2)
Early Phase 1 (1)
Phase 3 (1)
Phase 4 (2)

Trial Status

Unknown3
Completed2
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (6)

Research Network

Common Treatments

  • Adtsecondgeneration Antiandrogens Chemotherapy1
  • Silver Ions Dressing1
  • Fesia Grasp1
  • Globus Elite1
  • Cytoreductive Prostatectomy Or Brachytherapy1

Active Sponsors

  • Affiliated Hospital of Nantong University1
  • CNR Pisa1
  • Artvin Coruh University1
  • Università Foro Italico Roma1
  • Affiliated Hospital of Jiangnan University1

Top Investigators

Related Conditions

  • Parkinson Disease1
  • Metabolic Disease1
  • Electrode Site Reaction1
  • Diabetic Foot Ulcer1
  • Gait Analysis1

Activity Timeline